Tarsus Pharmaceuticals shared its Q3 2026 earnings, showing record sales of $194.6 million and raising its yearly sales forecast.

Nov 3, 2026, 5:49 PM ETResultsRead the original at Benzinga

Good for TARS

Tarsus reported record sales, strong XDEMVY prescription use, and raised its 2026 sales forecast. Its possible new medicines and overseas plans are not yet sales, but the results for its main drug point to stronger business prospects.

TARS · Tarsus Pharmaceuticals

AI read · Good for TARS

The AI's read

Patients are using XDEMVY more, and the drug is driving Tarsus's sales growth. About 93 cents of each sales dollar remained after product costs. The five possible medicines and overseas plans add future possibilities, but they are not current sales. The strong results for its main drug are the clearest sign of progress.

Get alerts for TARS

Follow Tarsus Pharmaceuticals (TARS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TARS

Free on the App Store and Google Play, or on the web.